CAPR revenueFY2025$0
- FY YoY
- -100.0%
CAPR revenue was $0 for fiscal 2025 (ended Dec 31, 2025), down 100.0% from fiscal 2024.
Capricor Therapeutics Inc. (CAPR) financials
For fiscal 2025 (ended Dec 31, 2025), Capricor Therapeutics Inc. reported $0 of revenue and -$105.04M of net income.
- Revenue, FY2025
- $0
- Revenue growth, YoY
- -100.0%
- Net income, FY2025
- -$105.04M
- Free cash flow, FY2025
- -$72.72M
- EPS, diluted, FY2025
- -$2.26
- Cash
- $20.94M
- Market cap
- $515.7M
FY2016FY2025
FY2016FY2025
FY2016FY2025
CAPR revenue and earnings growth
CAPR net incomeQ2 2026-$40.73M
CAPR net income was -$40.73M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$25.91M a year earlier. For the full fiscal 2025 it was -$105.04M, compared with -$40.47M in fiscal 2024.
CAPR EPSQ2 2026-$0.70
CAPR diluted EPS was -$0.70 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.57 a year earlier. For the full fiscal 2025 it was -$2.26, compared with -$1.15 in fiscal 2024.
CAPR free cash flowQ2 2026-$35.55M
CAPR free cash flow was -$35.55M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$20.41M a year earlier. For the full fiscal 2025 it was -$72.72M, compared with -$41.16M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $22.27M | $25.18M | $2.55M | $244.9K | $310.3K | $1.01M | $1.67M | $2.67M | $4.00M |
| Research and development | $84.45M | $49.97M | $36.45M | $21.82M | $13.57M | $8.46M | $5.14M | $12.07M | $10.77M | $16.04M |
| Selling, general and admin | $23.69M | $14.87M | $12.81M | $10.43M | $7.61M | $5.54M | $3.60M | $4.93M | $4.76M | $4.93M |
| Operating income | -$108.14M | -$42.56M | -$24.08M | -$29.70M | -$20.94M | -$13.69M | -$7.73M | -$15.33M | -$12.86M | -$16.98M |
| Interest expense | $3.05M | $0 | - | - | - | - | - | $0 | $398.8K | $344.7K |
| Pre-tax income | -$105.04M | -$40.47M | - | - | - | - | - | - | - | - |
| Income tax | $1.6K | $1.6K | - | - | - | - | - | - | - | - |
| Net income | -$105.04M | -$40.47M | -$22.29M | -$29.02M | -$20.02M | -$13.66M | -$7.64M | -$15.19M | $2.43M | -$18.81M |
| EPS, basic | -$2.26 | -$1.15 | -$0.83 | -$1.18 | -$0.87 | -$0.88 | -$2.06 | -$5.17 | $1.00 | -$10.10 |
| EPS, diluted | -$2.26 | -$1.15 | -$0.83 | -$1.18 | -$0.87 | -$0.88 | -$2.06 | -$5.17 | $0.90 | -$10.10 |
| Diluted shares | 46.5M | 35.2M | 26.8M | 24.6M | 23.1M | 15.6M | 3.7M | 2.9M | 2.7M | 1.9M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $287.85M | $11.29M | $14.69M | $9.60M | $34.89M | $32.67M | $3.90M | $4.55M | $6.88M | $4.55M |
| Short-term investments | - | $140.23M | $24.79M | $31.82M | $0 | - | $5.99M | $3.00M | $7.98M | $12.99M |
| Current assets | $322.94M | $163.39M | $50.86M | $42.89M | $36.44M | $33.68M | $10.54M | $8.47M | $15.71M | $18.11M |
| Total assets | $355.95M | $170.48M | $58.73M | $50.09M | $41.33M | $34.62M | $11.11M | $9.25M | $16.27M | $18.75M |
| Current liabilities | $35.84M | $21.03M | $31.27M | $23.59M | $4.13M | $2.97M | $898.0K | $1.26M | $1.67M | $4.90M |
| Total liabilities | $50.16M | $25.02M | $36.13M | $38.31M | $9.96M | $6.42M | $4.27M | $4.63M | $5.05M | $22.75M |
| Shareholders' equity | $305.79M | $145.46M | $22.60M | $11.79M | $31.37M | $28.20M | $6.84M | $4.62M | $11.23M | -$4.00M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$69.81M | -$40.00M | -$25.60M | $4.92M | -$16.81M | -$10.05M | -$6.82M | -$13.86M | -$14.23M | -$14.45M |
| Capital expenditures | $2.90M | $1.17M | $1.31M | $2.00M | $1.20M | $547.6K | $0 | $316.5K | $32.2K | $192.0K |
| Free cash flow | -$72.72M | -$41.16M | -$26.91M | $2.92M | -$18.01M | -$10.60M | -$6.82M | -$14.18M | -$14.26M | -$14.65M |
| Investing cash flow | $97.48M | -$116.18M | $5.11M | -$35.07M | -$1.20M | $5.44M | -$3.00M | $4.67M | $4.98M | -$5.19M |
| Financing cash flow | $248.89M | $152.77M | $25.58M | $4.87M | $20.23M | $33.38M | $9.18M | $6.85M | $11.58M | $18.63M |
| Share repurchases | - | - | - | - | - | $0 | $193 | $0 | - | - |
| Stock-based compensation | - | $9.77M | $7.39M | $4.46M | $2.97M | $1.95M | $701.0K | $1.73M | $1.71M | $1.96M |
| Depreciation and amortization | $1.89M | $1.43M | $1.07M | $533.1K | $245.7K | $143.9K | $172.0K | $157.7K | $144.2K | $125.7K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -100.0% | -11.5% | 886.8% | 941.8% | -21.1% | -69.1% | -39.9% | -37.3% | -33.3% | -27.5% |
| Operating margin | - | -191.1% | -95.6% | -1163.9% | -8549.9% | -4412.6% | -769.5% | -917.0% | -482.4% | -424.6% |
| Net margin | - | -181.7% | -88.5% | -1137.4% | -8175.9% | -4401.9% | -760.4% | -908.9% | 91.2% | -470.3% |
| Free cash flow margin | - | -184.8% | -106.9% | 114.3% | -7352.3% | -3417.4% | -678.7% | -848.3% | -534.9% | -366.3% |
| Return on equity | -34.4% | -27.8% | -98.6% | -246.2% | -63.8% | -48.4% | -111.7% | -329.1% | 21.7% | - |
| Return on assets | -29.5% | -23.7% | -37.9% | -57.9% | -48.4% | -39.4% | -68.8% | -164.3% | 14.9% | -100.3% |
| Current ratio | 9.01 | 7.77 | 1.63 | 1.82 | 8.82 | 11.33 | 11.74 | 6.75 | 9.40 | 3.70 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | $11.13M | $2.26M | $3.97M | $4.91M | $12.09M | $6.19M |
| Research and development | $28.87M | $27.38M | $23.13M | $20.36M | $22.05M | $18.92M | $14.55M | $11.81M | $12.50M | $11.10M | $9.94M | $10.03M |
| Selling, general and admin | $14.08M | $9.40M | $6.02M | $5.92M | $5.67M | $6.07M | $4.27M | $3.46M | $3.06M | $4.07M | $3.43M | $3.02M |
| Operating income | -$42.95M | -$36.77M | -$29.16M | -$26.28M | -$27.72M | -$24.98M | -$7.70M | -$13.01M | -$11.59M | -$10.27M | -$1.28M | -$6.86M |
| Pre-tax income | -$40.73M | -$33.94M | - | - | -$25.91M | -$24.39M | - | - | - | - | - | - |
| Income tax | $1.6K | $0 | - | - | $1.6K | $0 | - | - | - | - | - | - |
| Net income | -$40.73M | -$33.94M | -$30.17M | -$24.57M | -$25.91M | -$24.39M | -$7.12M | -$12.56M | -$11.00M | -$9.79M | -$762.1K | -$6.39M |
| EPS, basic | -$0.70 | -$0.59 | -$0.62 | -$0.54 | -$0.57 | -$0.53 | -$0.11 | -$0.38 | -$0.35 | -$0.31 | $0.02 | -$0.25 |
| EPS, diluted | -$0.70 | -$0.59 | -$0.62 | -$0.54 | -$0.57 | -$0.53 | -$0.11 | -$0.38 | -$0.35 | -$0.31 | $0.02 | -$0.25 |
| Diluted shares | 57.9M | 57.4M | - | 45.7M | 45.7M | 45.6M | - | 33.1M | 31.8M | 31.4M | - | 25.8M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $20.94M | $105.42M | $287.85M | $19.51M | $23.24M | $28.79M | $11.29M | $68.38M | $10.69M | $6.21M | $14.69M | $8.98M |
| Short-term investments | - | - | - | $79.06M | $99.56M | $115.98M | $140.23M | $16.65M | $18.77M | $33.70M | $24.79M | $19.54M |
| Current assets | $242.13M | $283.09M | $322.94M | $100.95M | $124.13M | $146.25M | $163.39M | $85.82M | $30.67M | $41.41M | $50.86M | $29.53M |
| Total assets | $368.74M | $326.28M | $355.95M | $126.44M | $133.57M | $153.77M | $170.48M | $92.95M | $38.28M | $49.44M | $58.73M | $37.15M |
| Current liabilities | $32.96M | $33.64M | $35.84M | $28.15M | $28.40M | $22.34M | $21.03M | $20.48M | $22.35M | $26.38M | $31.27M | $32.93M |
| Total liabilities | $122.52M | $47.58M | $50.16M | $42.57M | $28.59M | $26.12M | $25.02M | $24.69M | $26.78M | $31.01M | $36.13M | $38.94M |
| Shareholders' equity | $246.22M | $278.70M | $305.79M | $83.87M | $104.98M | $127.65M | $145.46M | $68.26M | $11.50M | $18.43M | $22.60M | -$1.79M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$31.49M | -$29.25M | -$23.57M | -$19.69M | -$20.12M | -$6.43M | -$14.80M | -$11.64M | -$12.29M | -$1.27M | -$11.59M | -$8.79M |
| Capital expenditures | $4.06M | $5.12M | $1.66M | $55.8K | $287.7K | $896.0K | $488.8K | $9.1K | $60.3K | $608.6K | $558.6K | $269.5K |
| Free cash flow | -$35.55M | -$34.38M | -$25.23M | -$19.74M | -$20.41M | -$7.33M | -$15.29M | -$11.65M | -$12.35M | -$1.88M | -$12.15M | -$9.06M |
| Investing cash flow | -$48.76M | -$154.64M | $43.09M | $15.95M | $14.55M | $23.89M | -$123.38M | $2.00M | $14.70M | -$9.50M | -$5.86M | $7.72M |
| Financing cash flow | -$4.24M | $1.47M | $248.82M | $7.0K | $19.6K | $50.4K | $81.09M | $67.33M | $2.07M | $2.29M | $23.17M | $221.1K |
| Stock-based compensation | - | - | - | - | - | - | $2.30M | $2.05M | $2.15M | $3.27M | $1.86M | $1.72M |
| Depreciation and amortization | $561.8K | $534.7K | $502.6K | $494.7K | $486.3K | $405.4K | $375.7K | $361.2K | $356.9K | $331.4K | $307.6K | $276.5K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | - | -7.9% | -63.4% | 1.4% | 64.3% | 1159.3% | 288.7% |
| Operating margin | - | - | - | - | - | - | -69.1% | -575.2% | -291.9% | -209.2% | -10.6% | -111.0% |
| Net margin | - | - | - | - | - | - | -63.9% | -555.2% | -277.0% | -199.6% | -6.3% | -103.3% |
| Free cash flow margin | - | - | - | - | - | - | -137.3% | -515.2% | -310.9% | -38.3% | -100.5% | -146.5% |
| Current ratio | 7.35 | 8.42 | 9.01 | 3.59 | 4.37 | 6.55 | 7.77 | 4.19 | 1.37 | 1.57 | 1.63 | 0.90 |
Source: XBRL data Capricor Therapeutics Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Aug 8, 2019.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
CAPR peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CAPR | $0 | -100.0% | -$105.04M | - | $515.7M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.35T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $675.92B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $519.48B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $364.98B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $311.52B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.61B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.31B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $180.22B |
CAPR FAQ
8 questionsWhat is CAPR revenue?
Capricor Therapeutics Inc. (CAPR) reported $0 of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 100.0% from the year before.Is CAPR profitable?
No. Capricor Therapeutics Inc. reported a net loss of $105.04M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does CAPR have?
Capricor Therapeutics Inc. reported $20.94M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is CAPR revenue growing?
Capricor Therapeutics Inc.'s revenue changed -100.0% in fiscal 2025, to $0.What is CAPR free cash flow?
Capricor Therapeutics Inc. generated -$72.72M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$69.81M less capital expenditures.What is CAPR earnings per share?
Diluted earnings per share were -$2.26 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did CAPR last report financial results?
The latest statements here come from Capricor Therapeutics Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.Where does this CAPR financial data come from?
Quantisnow builds these statements from the structured XBRL data Capricor Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.